In the News: Sino-US Scientific Cooperation; AstraZeneca Splits Its China Operation?; and Italy Limits Influence of Chinese Company

Jun 21, 2023
| By Clarence Lee
The U.S. government is debating whether to renew the U.S.-China Science and Technology Agreement; AstraZeneca plans to break up its business in China and list it separately in Hong Kong; the Italian government applies Golden Power regulations to limit the influence of China’s Sinochem on tyremaker Pirelli

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

This premium content is reserved for
China Law & Practice Subscribers.

A Premium Subscription Provides:

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment


Subscribe Now

For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].